BIA Separations, recently acquired by Sartorius, develops and manufactures market-leading CIM® monolithic chromatographic columns for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are applied in cell and gene therapies. BIA's technology for manufacturing-scale purification is already used in production of the first commercialized advanced therapeutics; BIA also has a keen presence with novel drug candidates in the clinical pipeline. Expecting continued strong double-digit sales growth over the next few years, BIA earned sales revenue approx. 25 million Euros in 2020, contributing to Sartorius Bioprocess Solutions, part of the Sartorius Group.
Cold Chain Technologies
With over 50 years of experience, we at Cold Chain Technologies (CCT), LLC, understand the logistics, applications, and requirements that the specialty pharmacy industry faces. We are actively supporting the temperature-sensitive supply chain requirements of several of the COVID-19 vaccines with the industry’s broadest portfolio of single-use and reusable systems. Our cutting-edge ISO 9001:2015, ISTA-certified, cGMP-compliant lab can do the testing and qualifying for your shipping lanes. We offer compliance documentation for regulatory and accreditation audits, as well as PQ study kits and services. Our superior pre-qualified solutions enable the pharmaceutical industry to meet their temperature, regulatory, cost-per-dose, and compliance challenges head on to get their products to those who need them most. With KoolTemp ReNew, we offer turn-key programs aimed on reducing landfill waste normally associated with the disposal of your temperature sensitive packaging. You can make the same number of shipments with nearly 90% fewer shippers and reduce required warehouse or freezer space and pack-out time with preconditioned units. CCT has the experience working with manufacturers and distributors alike in developing and then shipping mRNA therapies to patients’ arms with reliable and cost-effective shipping solutions and conditioning programs.
Cytiva is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. We have a rich heritage tracing back hundreds of years, and a fresh beginning since 2020.
Our customers undertake life-saving activities ranging from fundamental biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Our job is to supply the tools and services they need to work better, faster and safer, leading to better patient outcomes.
Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.
Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion.
Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter
AexeRNA Therapeutics is developing mRNA therapeutics utilizing its proprietary next generation tunable and highly potent Lipid Nanoparticle (LNP) nucleic acid delivery system. The AexLNP system was developed by Michael Buschmann at George Mason University and Drew Weissman at the University of Pennsylvania. In addition to our own therapeutic pipeline, AexeRNA provides our partners with a turn-key, best-in-class, IP-independent, mRNA LNP delivery platform technology for their mRNA therapeutics programs.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 27,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.